ALZpath's pTau217 antibody anchors 86 presentations at AAIC 2026 as blood-based biomarker research reaches 205 studies

Eighty-six presentations at the Alzheimer's Association International Conference 2026 center on one proprietary instrument: ALZpath's pTau217 antibody. The presentations span clinical and diagnostic value across the translational pipeline. Behind those 86 talks sits a body of 205 original research articles documenting the antibody's use in Alzheimer's blood-based biomarker research.

The print: 86 and 205

The 86-presentation count and the 205-article published record are the two numbers defining ALZpath's diagnostic footprint at AAIC 2026. ALZpath, Inc. describes itself as a leading developer of innovative diagnostic tools for Alzheimer's disease. The company reported the conference presence on July 13, 2026, from Carlsbad, Calif.

The pTau217 antibody is the instrument connecting clinical and diagnostic findings across all 86 presentations. ALZpath says those presentations demonstrate value spanning the translational pipeline. The 205 original articles are the peer-reviewed record built up as researchers have used the antibody across Alzheimer's blood-based biomarker studies, and the company says the current conference showing builds directly on that base.

Reading the setup

The scope of the AAIC appearance reflects the reach of ALZpath's current diagnostic program. Eighty-six presentations anchored to a single antibody represent a concentrated conference footprint for a Carlsbad-based company whose entire public-facing research record runs to 205 original studies.

ALZpath has not disclosed pricing, revenue guidance, or a definitive agreement in connection with the conference. No public ticker is listed for the company. The 205 original research articles remain the documented record to follow as AAIC 2026 data from those 86 presentations enters the published literature.